Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Cortes, Jorge E., Faderl, Stefan, Pagel, John, Jung, Chul Won, Yoon, Sung-Soo, Koh, Youngil, Pardanani, Animesh Dev, Hauptschein, Robert S, Lee, Kyoung-June, Lee, Je-Hwan | ||||||||||||
Title | Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). | ||||||||||||
|
|||||||||||||
URL | http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7044 | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CTNNB1 amp | acute myeloid leukemia | predicted - sensitive | CWP232291 | Phase I | Actionable | In a Phase I trial, CWP232291 reduced beta-catenin expression and demonstrated safety and preliminary efficacy in acute myeloid leukemia (J Clin Oncol (Meeting Abstracts) 2015 33: 7044)). | detail... |